Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Free Cash Flow (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Free Cash Flow data on record, last reported at -$28.5 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 344.63% year-over-year to -$28.5 million; the TTM value through Sep 2025 reached -$76.4 million, up 20.75%, while the annual FY2024 figure was -$67.4 million, 70.08% up from the prior year.
  • Free Cash Flow reached -$28.5 million in Q3 2025 per SGMO's latest filing, down from -$18.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $11.6 million in Q3 2024 and bottomed at -$76.5 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$44.9 million, with a median of -$50.0 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 4196.9% in 2021, then skyrocketed 123.27% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$75.3 million in 2021, then soared by 32.45% to -$50.9 million in 2022, then soared by 36.14% to -$32.5 million in 2023, then soared by 89.22% to -$3.5 million in 2024, then tumbled by 713.16% to -$28.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$28.5 million in Q3 2025, -$18.0 million in Q2 2025, and -$26.4 million in Q1 2025.